	US 12,234,294 B2
	Pharmaceutical composition of a humanized anti-CD40 antibody
James Kranz, Lexington, MA (US)
Assigned to Kiniksa Pharmaceuticals, GmbH, Zug (CH)
Filed by Kiniksa Pharmaceuticals, GmbH, Zug (CH)
Filed on Nov. 1, 2022, as Appl. No. 18/051,833.
Claims priority of provisional application 63/276,388, filed on Nov. 5, 2021.
Prior Publication US 2023/0203179 A1, Jun. 29, 2023
Int. Cl. C07K 16/28 (2006.01); A61K 9/00 (2006.01); A61K 39/395 (2006.01); A61K 47/18 (2017.01)

CPC C07K 16/2878 (2013.01) [A61K 9/0019 (2013.01); A61K 39/39591 (2013.01); A61K 47/183 (2013.01); C07K 2317/24 (2013.01); C07K 2317/56 (2013.01)]

8 Claims

1. A pharmaceutical composition formulated for intravenous injection comprising 200 mg/ml of an anti-CD40 antibody or antigen-binding fragment thereof comprising a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 1, and a light chain comprising the amino acid sequence set forth in SEQ ID NO: 2, wherein the pharmaceutical composition comprises 0.02% polysorbate 20, 50 mM sodium acetate, 100 mM arginine, and 100 mM glutamate, a pH of 5.4.